Malaysiakini
NEWS

Gilead prices Covid-19 drug candidate Remdesivir at US$2,340 per patient

Reuters

Published

Gilead Sciences Inc has priced its Covid-19 drug candidate Remdesivir at US$2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at US$390.

The price for US private insurance companies will be US$520 per vial, the drugmaker said, which equates to US$3,120 per patient for a treatment course using six vials of Remdesivir.

All Access Plan
starting from

~RM12

per month
Subscribe Now
You can cancel anytime.
Get unlimited access to our articles on web and apps
Add comments to our articles
Bookmark articles to read later
We accept
Already Subscribed?
Sign In

Share this story